Skip to main content
Clinical Trials/NCT01426321
NCT01426321
Completed
N/A

Individually Tailored Cardiac Resynchronization Therapy - Combing Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in Cardiac Resynchronization Therapy

Region Skane1 site in 1 country100 target enrollmentAugust 2011
ConditionsHeart Failure

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Region Skane
Enrollment
100
Locations
1
Primary Endpoint
Positive response to CRT treatment
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

For patients with advanced heart failure, Cardiac Resynchronization Therapy (CRT) has been a major improvement. The treatment improves symptoms and prolongs life in selected patients with heart failure. However, with the current selection criteria and methods for implanting the pacemaker, only 60-70% of the patients derive significant benefit from the treatment.

New imaging techniques, including advanced ultrasound and computed tomography, in combination with new versatile multi-pole electrodes, have made an individually tailored therapy possible. Using these techniques in combination, the study will investigate the effect of individually based "optimal" placement of the pacemaker electrodes vs. standard care. The optimal LV electrode position is defined as pacing a viable segment with the latest mechanical delay, targeting a specific segment of the coronary sinus as visualised on cardiac CT. The hypothesis is that this will increase the number of positive responders from 65% to 85%.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
December 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Symptomatic heart failure (New York Heart Association functional class II - IV) despite stabile optimal medical therapy.
  • Wide QRS ≥ 120 milliseconds on standard ECG.
  • LV systolic dysfunction (EF ≤ 35%).
  • Written informed consent.
  • Accepted for CRT-P or CRT-D treatment

Exclusion Criteria

  • Life expectancy \< 12 months.
  • Recent myocardial infarction (\< 3 months).
  • Significant valve disease
  • Chronic atrial fibrillation
  • Pregnancy
  • Severely impaired renal function (estimated glomerular filtration rate (eGFR) \< 30 ml/min)
  • Unable to give written informed consent.

Outcomes

Primary Outcomes

Positive response to CRT treatment

Time Frame: 6 months

The primary efficacy endpoint will evaluate the effect of echocardiography and cardiac CT guided placement of the left ventricular lead vs standard care (i.e. position of the left ventricular lead at the discretion of the treating physician). Number of patients with positive response to CRT (YES or NO). A positive response is defined as survival in combination with either a reduction in end systolic left ventricular volume ≥ 15% by echocardiography ("volume responder") and / or improvement ≥ 1 NYHA class and ≥10% improvement in 6 minute hall walk test ("clinical responder").

Secondary Outcomes

  • Quality of life(6 months 2 years 5 years)
  • Ventricular tachycardia(6 months 2 years and 5 years)
  • Heart failure morbidity(6 months 2 years and 5 years)
  • Myocardial viability(6 months)
  • Biochemical markers of heart failure(6 months)
  • Left ventricular systolic function(6 months)
  • Response to CRT (on-treatment analysis)(6 months)
  • Mortality(6 months, 2 years and 5 years)
  • Left ventricular dyssynchrony(6 months)
  • Left ventricular diastolic dimension(6 months)
  • Morbidity and mortality(6 months 2 years and 5 years)
  • MRI left ventricular dyssynchrony(6 months)

Study Sites (1)

Loading locations...

Similar Trials